"Moderna's 2023 Financial Results: Surprise Profit and RSV Vaccine Roadmap"

Moderna reports fourth quarter revenues of $2.8 billion, GAAP net income of $217 million, and full-year revenues of $6.8 billion, primarily driven by COVID-19 vaccine sales. The company reaffirms its 2024 expected product sales of approximately $4 billion and expects regulatory approvals for its investigational RSV vaccine for older adults beginning in the first half of 2024. Moderna also provides updates on its commercial efforts, financial results, 2024 financial framework, and upcoming late-stage pipeline milestones across vaccines and therapeutics.